MX2019012909A - Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos. - Google Patents

Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Info

Publication number
MX2019012909A
MX2019012909A MX2019012909A MX2019012909A MX2019012909A MX 2019012909 A MX2019012909 A MX 2019012909A MX 2019012909 A MX2019012909 A MX 2019012909A MX 2019012909 A MX2019012909 A MX 2019012909A MX 2019012909 A MX2019012909 A MX 2019012909A
Authority
MX
Mexico
Prior art keywords
masp
inhibitory agent
disease
compositions
subject
Prior art date
Application number
MX2019012909A
Other languages
English (en)
Inventor
Patrick Gray
Gregory A Demopulos
Hans-Wilhelm Schwaeble
Thomas Dudler
Original Assignee
Omeros Coporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49769678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019012909(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Coporation filed Critical Omeros Coporation
Publication of MX2019012909A publication Critical patent/MX2019012909A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En un aspecto, la invención proporciona métodos y composiciones para inhibir la activación del complemento dependiente de MASP-3 en un sujeto sujeto que padece de, o está en riesgo de desarrollar, una enfermedad o trastorno seleccionado del grupo que consiste de degeneración macular relacionada con la edad, artritis, coagulación intravascular diseminada, microangiopatía trombótica, asma, enfermedad de depósitos densos, glomerulonefritis crescéntica necrotizante y pauci-inmune, lesión cerebral traumática, neumonía por aspiración, endoftalmitis, neuromielitis óptica y enfermedad de Behcet al administrar al sujeto una composición que comprende una cantidad de un agente inhibidor de MASP-3 en una cantidad eficaz para inhibir la activación del complemento dependiente de MASP-3. En algunas modalidades, al sujeto se le administra un agente inhibidor de MASP-2 y un agente inhibidor de MASP-1, un agente inhibidor de MASP-2 y un agente inhibidor de MASP-3, un agente inhibidor de MASP-3 y un agente inhibidor de MASP-1, o un agente inhibidor de MASP-1, un agente inhibidor de MASP-2 y un agente inhibidor de MASP-3.
MX2019012909A 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos. MX2019012909A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261661167P 2012-06-18 2012-06-18

Publications (1)

Publication Number Publication Date
MX2019012909A true MX2019012909A (es) 2020-12-10

Family

ID=49769678

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014015715A MX2014015715A (es) 2012-06-18 2013-06-18 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2020005700A MX2020005700A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2019012909A MX2019012909A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2014015715A MX2014015715A (es) 2012-06-18 2013-06-18 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2020005700A MX2020005700A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Country Status (27)

Country Link
US (3) US20130344073A1 (es)
EP (4) EP3878865A3 (es)
JP (4) JP6445972B2 (es)
KR (4) KR102339315B1 (es)
CN (3) CN115040653A (es)
AU (3) AU2013277309B2 (es)
BR (1) BR112014031522A2 (es)
CA (2) CA3214532A1 (es)
CL (2) CL2014003455A1 (es)
CY (1) CY1124234T1 (es)
DK (1) DK2861246T3 (es)
ES (1) ES2864857T3 (es)
HK (1) HK1209623A1 (es)
HR (1) HRP20210559T1 (es)
HU (1) HUE053727T2 (es)
IL (2) IL236327B (es)
IN (1) IN2015KN00015A (es)
LT (1) LT2861246T (es)
MX (3) MX2014015715A (es)
NZ (1) NZ629473A (es)
PL (1) PL2861246T3 (es)
PT (1) PT2861246T (es)
RS (1) RS61755B1 (es)
RU (2) RU2019140356A (es)
SI (1) SI2861246T1 (es)
WO (1) WO2013192240A2 (es)
ZA (1) ZA201500094B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
ES2683307T3 (es) 2011-04-08 2018-09-26 University Of Leicester Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
US9217042B2 (en) * 2012-10-23 2015-12-22 Abbott Cardiovascular Systems Inc. Method of reducing MACE in diabetic patients subsequent to stent placement
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CA2906096C (en) 2013-03-15 2022-03-15 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
US20160053023A1 (en) * 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
ES2753419T3 (es) 2013-06-07 2020-04-08 Univ Duke Inhibidores del factor H del complemento
MX2015017341A (es) 2013-07-09 2016-07-06 Anexxon Inc Anticuerpos anti-factor del complemento c1q y uso de los mismos.
CN105683219B (zh) 2013-10-17 2020-07-14 奥默罗斯公司 用于治疗与masp-2依赖性补体活化有关的病况的方法
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
CA2951159A1 (en) * 2014-06-05 2015-12-10 The Regents Of The University Of Colorado, A Body Corporate Map44 polypeptides and constructs based on natural antibodies and uses thereof
KR102626877B1 (ko) 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 인간화 항-보체 인자 c1q 항체 및 이의 용도
US10639307B2 (en) 2015-05-15 2020-05-05 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
EP3302578A4 (en) * 2015-06-03 2019-03-13 Coyne Scientific, LLC METHOD OF ESTABLISHING THRESHOLD LIMITS FOR A CHEMICAL OR BIOLOGICAL AGENT IN A TARGET SPECIES
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
MX2018005165A (es) * 2015-11-09 2020-11-11 Omeros Corp Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
CN108779171B (zh) 2015-11-24 2022-07-05 安尼艾克松股份有限公司 抗补体因子c1q的fab片段及其应用
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
CA3018774C (en) * 2016-03-31 2023-02-28 Omeros Corporation Methods for inhibiting angiogenesis in a subject in need thereof
JOP20170154B1 (ar) 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
KR102632860B1 (ko) 2017-03-01 2024-02-02 아칠리온 파르마세우티칼스 인코포레이티드 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
WO2018186322A1 (en) * 2017-04-03 2018-10-11 Chugai Seiyaku Kabushiki Kaisha Anti-masp-1 antibodies and methods of use
EP3672994A4 (en) * 2017-08-25 2021-06-02 Omeros Corporation HIGHLY CONCENTRATED LOW VISCOSITY MASP-2 INHIBITIVE ANTIBODY FORMULATIONS, KITS, AND METHODS FOR TREATING PEOPLE WITH ATYPICAL HEMOLYTIC SYNDROME
WO2019198807A1 (en) * 2018-04-13 2019-10-17 Chugai Seiyaku Kabushiki Kaisha Anti-complement component antibodies and methods of use
MX2020013755A (es) * 2018-06-22 2021-05-12 Omeros Corp Composiciones y metodos de inhibicion de masp-2 para el tratamiento de diversas enfermedades y trastornos tromboticos.
AU2019336238A1 (en) 2018-09-06 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of Complement factor D inhibitors
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3856164A4 (en) 2018-09-25 2022-07-13 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
PE20220431A1 (es) 2019-05-07 2022-03-29 Bayer Ag Compuestos inhibidores de la masp y usos de estos
BR112022010881A2 (pt) 2019-12-04 2022-08-23 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
EP4069238A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
KR20220110530A (ko) 2019-12-04 2022-08-08 오메로스 코포레이션 Masp-2 억제자 및 사용 방법
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
CN112237630A (zh) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
TW202319069A (zh) * 2020-03-06 2023-05-16 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CN115215937B (zh) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN114989259B (zh) * 2022-05-27 2023-06-09 成都佩德生物医药有限公司 一种小分子肽Ped4及应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
ATE149841T1 (de) 1990-01-26 1997-03-15 Immunomedics Inc Impfstoffe gegen krebs und infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
AU785149B2 (en) * 1999-12-02 2006-10-05 Jens Christian Jensenius MASP-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
CN1652813A (zh) * 2002-03-15 2005-08-10 纳蒂芒公司 包含甘露糖结合凝集素的药用组合物
US7297348B2 (en) 2002-07-19 2007-11-20 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
JP2006518749A (ja) * 2003-02-21 2006-08-17 タノックス インコーポレーテッド 虚血再灌流障害に伴う組織損傷を予防及び治療するための方法
ATE501728T1 (de) * 2003-07-08 2011-04-15 Umc Utrecht Holding Bv Therapeutische verwendung von lpi, einem inhibitor des lectinwegs in staphylokokken bei entzündungskrankheiten
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2386316B1 (en) * 2004-06-10 2018-02-28 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN100518905C (zh) * 2004-11-02 2009-07-29 浙江欧美环境工程有限公司 折返式电除盐器
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CN101370525B (zh) 2005-08-19 2013-09-18 Abbvie公司 双重可变结构域免疫球蛋白及其用途
EP1940457B1 (en) * 2005-10-21 2012-12-12 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
EP1991275B1 (en) * 2006-03-08 2014-11-05 Archemix LLC Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
WO2009029315A2 (en) 2007-05-31 2009-03-05 University Of Washington Inducible mutagenesis of target genes
HRP20230167T1 (hr) * 2008-11-10 2023-03-31 Alexion Pharmaceuticals, Inc. Postupci i pripravci za liječenje poremećaja povezanih s komplementom
MX2011013748A (es) * 2009-06-23 2012-04-20 Alexion Pharma Inc Anticuerpos biespecificos que se unen a proteinas de complemento.
EP3395828A1 (en) * 2009-07-17 2018-10-31 Rigshospitalet Inhibitors of complement activation
CA2971474C (en) * 2009-10-16 2022-11-22 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
JP6148013B2 (ja) * 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
ES2683307T3 (es) * 2011-04-08 2018-09-26 University Of Leicester Métodos para tratar afecciones asociadas con la activación de complemento dependiente de MASP-2
IN2014KN02324A (es) * 2012-04-06 2015-05-01 Omeros Corp

Also Published As

Publication number Publication date
NZ728179A (en) 2021-12-24
EP4119577A3 (en) 2023-11-08
EP3878865A3 (en) 2021-12-08
AU2013277309A1 (en) 2015-01-22
IL261436B (en) 2021-08-31
RU2019140356A (ru) 2020-01-27
CA2875567C (en) 2023-11-14
PT2861246T (pt) 2021-04-05
JP6445972B2 (ja) 2018-12-26
EP2861246B1 (en) 2021-01-20
KR20220100997A (ko) 2022-07-18
HRP20210559T1 (hr) 2021-05-14
HUE053727T2 (hu) 2021-07-28
WO2013192240A2 (en) 2013-12-27
IL261436A (en) 2018-11-04
RU2015101230A (ru) 2016-08-10
CA2875567A1 (en) 2013-12-27
AU2020202999B2 (en) 2022-03-24
ZA201500094B (en) 2019-08-28
RS61755B1 (sr) 2021-05-31
JP2021006546A (ja) 2021-01-21
JP2019048881A (ja) 2019-03-28
PL2861246T3 (pl) 2021-10-25
CN109908352A (zh) 2019-06-21
HK1209623A1 (en) 2016-04-08
AU2018204285B2 (en) 2020-02-27
US20130344073A1 (en) 2013-12-26
KR102339315B1 (ko) 2021-12-15
JP2015521623A (ja) 2015-07-30
IL236327B (en) 2019-02-28
BR112014031522A2 (pt) 2017-08-01
CA3214532A1 (en) 2013-12-27
EP3878865A2 (en) 2021-09-15
KR20200116164A (ko) 2020-10-08
AU2020202999A1 (en) 2020-05-28
JP6771531B2 (ja) 2020-10-21
CL2016003297A1 (es) 2017-06-02
RU2709351C2 (ru) 2019-12-17
NZ629473A (en) 2017-02-24
CN104717975A (zh) 2015-06-17
LT2861246T (lt) 2021-04-26
SI2861246T1 (sl) 2021-08-31
CN115040653A (zh) 2022-09-13
KR20200015952A (ko) 2020-02-13
IN2015KN00015A (es) 2015-07-31
CL2014003455A1 (es) 2015-04-10
CY1124234T1 (el) 2022-05-27
US20190127484A1 (en) 2019-05-02
ES2864857T3 (es) 2021-10-14
EP3058951A1 (en) 2016-08-24
MX2020005700A (es) 2020-09-25
MX2014015715A (es) 2016-02-05
AU2013277309B2 (en) 2018-03-29
EP2861246A4 (en) 2016-03-23
KR20150031298A (ko) 2015-03-23
JP2022084946A (ja) 2022-06-07
EP2861246A2 (en) 2015-04-22
US20220259325A1 (en) 2022-08-18
EP4119577A2 (en) 2023-01-18
DK2861246T3 (en) 2021-04-26
WO2013192240A3 (en) 2014-07-03
IL236327A0 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
MX2019012909A (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
MX2016014634A (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
CY1119420T1 (el) Νεες θεραπευτικες προσεγγισεις για θεραπεια ασθενειας parkinson
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
TN2017000119A1 (en) Indole carboxamides compounds useful as kinase inhibitors
WO2013061161A3 (en) New combination therapies for treating neurological disorders
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX337548B (es) Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide.
PH12014502218A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
WO2016090024A3 (en) Combination therapy for treatment of cancer
NZ629675A (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
EP3818991A3 (en) Compositions and methods for treating diseases
MX2021006985A (es) Metodos para el tratamiento de la depresión.
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
PH12021550043A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
MX343366B (es) Peptidos de nd2 y metodos de tratamiento de enfermedad neurologica.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.